Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash & Equivalents (2019 - 2025)

IDEAYA Biosciences' Cash & Equivalents history spans 7 years, with the latest figure at $112.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 33.71% year-over-year to $112.8 million; the TTM value through Dec 2025 reached $112.8 million, up 33.71%, while the annual FY2025 figure was $112.8 million, 33.71% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $112.8 million at IDEAYA Biosciences, down from $298.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $400.3 million in Q3 2024 and bottomed at $49.1 million in Q2 2022.
  • The 5-year median for Cash & Equivalents is $108.4 million (2021), against an average of $130.7 million.
  • The largest annual shift saw Cash & Equivalents soared 285.63% in 2021 before it crashed 59.57% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $92.0 million in 2021, then decreased by 25.44% to $68.6 million in 2022, then surged by 128.78% to $157.0 million in 2023, then plummeted by 46.26% to $84.4 million in 2024, then skyrocketed by 33.71% to $112.8 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Cash & Equivalents are $112.8 million (Q4 2025), $298.9 million (Q3 2025), and $114.6 million (Q2 2025).